Treatment of Smox/Sat-1 double knock-out mice (Smox/Sat1-dKO) with transglutaminase inhibitors decreased the expression and aggregation of polyamines, reduced the severity of cerebellar damage, and significantly delayed the onset of ataxia [84]. The gene discussed is SMOX; the disease is Ataxia.